Switching innate immunity off: IL-1Ra, IL-10, SOCS and A20
- Process
Inflammation has built-in brakes; when a brake gene is missing, inflammation starts early in life and does not stop.
What it is
Innate responses must end once the threat is gone. Cells use soluble blockers (IL-1 receptor antagonist, decoy receptors), suppressive cytokines (IL-10, TGF-β) and intracellular brakes that switch signalling off (SOCS proteins on JAK–STAT, A20 on NF-κB). Single-gene loss of these brakes causes severe early inflammatory diseases, and the brakes themselves inspired drugs such as anakinra.
Key facts
- Anakinra is a recombinant form of the body’s own IL-1 receptor antagonist.
- Decoy receptors such as IL-1 receptor type II bind IL-1 without signalling.
- Many brakes are induced by the inflammatory signal itself: a built-in negative feedback loop.
Step by step
- A microbe triggers TLRs and IL-1 receptors; NF-κB turns on inflammatory genes.
- The same signals induce their own brakes: A20, SOCS proteins and IL-10.
- A20 removes ubiquitin chains that keep the NF-κB pathway active, ending the signal.
- SOCS proteins bind JAKs and cytokine receptors and stop STAT signalling.
- IL-10 from macrophages and regulatory T cells lowers IL-12, TNF and costimulator expression.
- IL-1 receptor antagonist occupies the IL-1 receptor without signalling, competing with IL-1.
Brakes of innate immunity and what happens without them
| Brake | How it works | Disease when missing |
|---|---|---|
| IL-1 receptor antagonist (IL1RN) | Blocks the IL-1 receptor | DIRA: newborn pustular rash, osteomyelitis and periostitis; responds to anakinra |
| IL-10 or IL-10 receptor | Suppresses macrophage and dendritic-cell activation | Very early-onset inflammatory bowel disease in infancy |
| A20 (TNFAIP3) | Deubiquitinase that ends NF-κB signalling | Haploinsufficiency of A20: early-onset Behçet-like disease; common variants linked to lupus and RA |
| SOCS proteins | Feedback inhibitors of JAK–STAT | Overactive cytokine signalling (reported mainly as rare variants) |
| TGF-β | Suppresses lymphocyte activation, promotes repair | Severe multiorgan inflammation in animal models |
Common traps
- Anakinra is a foreign molecule that blocks IL-1: it is a recombinant copy of the body's own IL-1 receptor antagonist, which is why it corrects DIRA.
- A20 is a kinase that switches NF-κB on: A20 is a deubiquitinase that switches NF-κB off, and losing one copy causes early Behçet-like disease.
- Colitis in a young infant is always milk allergy or infection: very early-onset IBD suggests IL-10 or IL-10 receptor deficiency, curable by stem cell transplant.
- Decoy receptors signal weakly: IL-1 receptor type II binds IL-1 without any signal, simply mopping it up.
Test yourself
Think of the answer, then tap the question to see it.
A newborn has a pustular rash and inflamed bones with high CRP and improves dramatically on anakinra. What is missing and why does the drug work?
The IL-1 receptor antagonist (DIRA); anakinra is the recombinant replacement, so it restores the missing brake on IL-1 signalling.
Why do inflammatory signals induce their own inhibitors, such as A20 and SOCS?
Negative feedback: the brake is made in proportion to the signal, so the response ends when the trigger falls instead of running on.
A baby develops severe colitis in the first months of life. Which cytokine pathway should be suspected?
IL-10 or its receptor: their loss causes very early-onset inflammatory bowel disease.
Connections
In Pharmacology1
Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.
Sources: Immune response (MedlinePlus, US National Library of Medicine, 2024); Crohn Disease (StatPearls (NCBI Bookshelf), 2024).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
